Evotec SE Stock

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra 11:35:52 2024-05-03 am EDT 5-day change 1st Jan Change
9.76 EUR -1.36% Intraday chart for Evotec SE +5.68% -54.14%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 880M 947M Sales 2025 * 1.05B 1.13B Capitalization 1.73B 1.86B
Net income 2024 * 10M 10.76M Net income 2025 * 57M 61.36M EV / Sales 2024 * 1.78 x
Net cash position 2024 * 161M 173M Net cash position 2025 * 180M 193M EV / Sales 2025 * 1.48 x
P/E ratio 2024 *
217 x
P/E ratio 2025 *
21.8 x
Employees 5,061
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.36%
1 week+5.68%
Current month+0.21%
1 month-30.83%
3 months-26.28%
6 months-44.32%
Current year-54.14%
More quotes
1 week
9.36
Extreme 9.355
10.17
1 month
8.52
Extreme 8.52
14.62
Current year
8.52
Extreme 8.52
21.42
1 year
8.52
Extreme 8.52
24.44
3 years
8.52
Extreme 8.52
45.83
5 years
8.52
Extreme 8.52
45.83
10 years
2.42
Extreme 2.42
45.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19-06-18
Director of Finance/CFO 51 23-02-06
Chief Operating Officer 54 12-04-30
Members of the board TitleAgeSince
Chief Executive Officer 61 19-06-18
Director/Board Member 56 19-06-18
Chairman 63 14-06-16
More insiders
Date Price Change Volume
24-05-03 9.76 -1.36% 1,942,958
24-05-02 9.895 +1.59% 2,643,919
24-04-30 9.74 +1.19% 2,200,310
24-04-29 9.625 +4.22% 3,576,901

Delayed Quote Xetra, May 03, 2024 at 11:35 am EDT

More quotes
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.76 EUR
Average target price
23.94 EUR
Spread / Average Target
+145.29%
Consensus